Humana — Jul 30, 2025 release

Box 1438 Louisville, KY 40202 http://www.humana.com FOR MORE INFORMATION CONTACT: Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com Mark Taylor Humana Corporate Communications (317) 753-0345 e-mail: MTaylor108@humana.com Humana Reports Second Quarter 2025 Financial Results; Raises Full Year 2025 Adjusted EPS and Revenue Guidance • Reports 2Q25 earnings per share (EPS) of $4.51 on a GAAP basis, Adjusted EPS of $6.27; reports YTD EPS of $14.81 on a GAAP basis, $17.85 on an Adjusted basis • 2Q25 Insurance segment benefit ratio of 89.9 percent, in line with the company's previously disclosed expectation of 'approximately 90 percent' • Updates FY 2025 GAAP EPS guidance to 'approximately $13.77' from the previous estimate of 'approximately $14.68'; raises Adjusted FY 2025 EPS guidance to 'approximately $17.00', up from the previous 'approximately $16.25' guidance • Raises FY 2025 consolidated revenues guidance to 'at least $128 billion' compared to the previous guidance range of $126 billion to $128 billion • Affirms FY 2025 Insurance segment benefit ratio guidance range of 90.1 percent to 90.5 percent • Revises FY 2025 individual Medicare Advantage membership guidance to now anticipate a decline of 'up to 500,000 members' from previous guidance of a decline of 'approximately 550,000' ◦ Expected membership decline inclusive of the impact of exiting certain unprofitable plans and counties ◦ Remains confident in 2025 pricing strategy as the company prioritizes benefit structure that is expected to drive sustainable, long-term value creation • Continues to strategically expand the company's footprint in CenterWell and Medicaid ◦ CenterWell Pharmacy recently won access to 17 new limited distribution drugs and won the MMIT Patient Choice award for the 7th time in 8 years of the program's history ◦ CenterWell Primary Care now anticipates FY 2025 net patient growth of 50,000 to 70,000, ahead of the previously expected range of 30,000 to 50,000, reflecting 15 percent growth at the midpoint ◦ Launched Virginia Medicaid contract in July, unlocking a new dual special needs plan (D-SNP) market growth opportunity • Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial result